{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:00Z","timestamp":1792783080995,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NSW Health EMCR Grant, Heart Foundation of Australia","id":[{"id":"https:\/\/ror.org\/039d9wr27","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>\n                      Pulsed field ablation (PFA) is increasingly used to treat patients with atrial fibrillation (AF). The RESET-AF was a single-arm, first-in-human, clinical trial of AF ablation using a novel, single-shot PFA system (ElePulse\n                      <jats:sup>\u00ae<\/jats:sup>\n                      , CRC EP, Tustin, CA, USA), trial registration ACTRN12622001523796 (Date registered 8th December 2022).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In 36 consecutively-enrolled patients (57\u2009\u00b1\u200911 years, 69% male) with symptomatic paroxysmal (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922) and persistent (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914) AF, pulmonary vein isolation (PVI) was performed using this catheter, guided by 3D mapping. All patients underwent remapping at 3 months to confirm PVI durability. Patients were followed at 6 and 12 months with clinical review, Holter monitoring and electrocardiography. The primary efficacy and safety endpoints included a freedom from recurrent AF at 12 months\u2009&gt;\u200950% and serious adverse events (SAE) at 7 and 30 days\u2009&lt;\u20095%, respectively. The secondary efficacy endpoints included 3-month PVI durability\u2009&gt;\u200950% and 6-month freedom from AF\u2009&gt;\u200960%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All endpoints were achieved in the entire study cohort. There was 1 SAE (renal impairment which resolved with conservative management) with a total SAE rate of 2.8%. One patient was lost to follow-up at 12 months with a primary efficacy endpoint of 92% (32\/35 patients). The secondary efficacy endpoints were 82% 3-month PVI and 94% (34\/36 patients) 6-month freedom from AF. During the study, the PFA dose was adjusted in 3 cohorts. The \u201coptimized subset\u201d had 100% PVI durability and freedom from AF at 6 and 12 months without SAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study of a novel PFA catheter system for ablation of paroxysmal and persistent AF achieved all predetermined primary and secondary clinical endpoints.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10840-026-02434-3","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:37:10Z","timestamp":1789641430000},"page":"1481-1491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-in-human experience from RESET-AF (Rapid onE-Shot Electroporation Trial for Atrial Fibrillation)"],"prefix":"10.1007","volume":"69","author":[{"given":"Paul A.","family":"Gould","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart P.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waheed","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre C.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2434_CR1","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jacep.2021.02.014","volume":"7","author":"VY Reddy","year":"2021","unstructured":"Reddy VY, Dukkipati SR, Neuzil P, Anic A, Petru J, Funasako M, et al. Pulsed Field Ablation of Paroxysmal Atrial Fibrillation: 1-Year Outcomes of IMPULSE, PEFCAT, and PEFCAT II. JACC Clin Electrophysiol. 2021;7:614\u201327.","journal-title":"JACC Clin Electrophysiol"},{"key":"2434_CR2","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.jacc.2020.07.007","volume":"76","author":"VY Reddy","year":"2020","unstructured":"Reddy VY, Anic A, Koruth JS, Petru J, Funasako M, Minami K, et al. Pulsed Field Ablation in Patients With Persistent Atrial Fibrillation. J Am Coll Cardiol. 2020;76:1068\u201380.","journal-title":"J Am Coll Cardiol"},{"key":"2434_CR3","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1161\/CIRCULATIONAHA.123.063988","volume":"147","author":"A Verma","year":"2023","unstructured":"Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal Trial. Circulation. 2023;147:1422\u201332.","journal-title":"Circulation"},{"key":"2434_CR4","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1056\/NEJMoa2307291","volume":"389","author":"VY Reddy","year":"2023","unstructured":"Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med. 2023;389:1660\u201371.","journal-title":"N Engl J Med"},{"key":"2434_CR5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jacc.2019.04.021","volume":"74","author":"VY Reddy","year":"2019","unstructured":"Reddy VY, Neuzil P, Koruth JS, Petru J, Funosako M, Cochet H, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019;74:315\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"2434_CR6","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1111\/jce.16010","volume":"34","author":"A Aryana","year":"2023","unstructured":"Aryana A, Ji SY, Hata C, de la Rama A, Nguyen K, Panescu D. Preclinical evaluation of a novel single-shot pulsed field ablation system for pulmonary vein and atrial ablation. J Cardiovasc Electrophysiol. 2023;34:2203\u201312.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2434_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s10840-023-01714-6","volume":"68","author":"A Aryana","year":"2025","unstructured":"Aryana A, Hata C, de la Rama A, Nguyen K, Panescu D. A novel pulsed field ablation system using linear and spiral ablation catheters can create large and durable endocardial and epicardial ventricular lesions in vivo. J Interv Card Electrophysiol. 2025;68:1417\u201328.","journal-title":"J Interv Card Electrophysiol"},{"key":"2434_CR8","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1093\/europace\/eus027","volume":"14","author":"H Calkins","year":"2012","unstructured":"Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. 2012 HRS\/EHRA\/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14:528\u2013606.","journal-title":"Europace"},{"key":"2434_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jacep.2019.12.015","volume":"6","author":"E Anter","year":"2020","unstructured":"Anter E, Neu\u017eil P, Rackauskas G, Peichl P, Aidietis A, Kautzner J, et al. A Lattice-Tip Temperature-Controlled Radiofrequency Ablation Catheter for Wide Thermal Lesions: First-in-Human Experience With Atrial Fibrillation. JACC Clin Electrophysiol. 2020;6:507\u201319.","journal-title":"JACC Clin Electrophysiol"},{"key":"2434_CR10","doi-asserted-by":"publisher","first-page":"euad147","DOI":"10.1093\/europace\/euad147","volume":"25","author":"A Ani\u0107","year":"2023","unstructured":"Ani\u0107 A, Thomas Phlips T, Bre\u0161kovi\u0107 T, Koopman P, Girouard S, Vikramaditya M, et al. Pulsed field ablation using focal contact force-sensing catheters for treatment of atrial fibrillation: acute and 90-day invasive remapping results. Europace. 2023;25:euad147.","journal-title":"Europace"},{"key":"2434_CR11","first-page":"e011780","volume":"16","author":"M Duytschaever","year":"2023","unstructured":"Duytschaever M, De Potter T, Grimaldi M, Anic A, Vijgen J, Neuzil P, et al. Paroxysmal Atrial Fibrillation Ablation Using a Novel Variable-Loop Biphasic Pulsed Field Ablation Catheter Integrated With a 3-Dimensional Mapping System: 1-Year Outcomes of the Multicenter inspIRE. Study Circ Arrhythm Electrophysiol. 2023;16:e011780.","journal-title":"Study Circ Arrhythm Electrophysiol"},{"issue":"5","key":"2434_CR12","doi-asserted-by":"publisher","first-page":"euae118","DOI":"10.1093\/europace\/euae118","volume":"26","author":"P Sanders","year":"2024","unstructured":"Sanders P, Healy S, Emami M, Kotschet E, Miller A, Kalman JM. Initial clinical experience with the balloon-in-basket pulsed field ablation system: acute results of the VOLT CE mark feasibility study. Europace. 2024;26(5):euae118.","journal-title":"Europace"},{"key":"2434_CR13","doi-asserted-by":"crossref","unstructured":"Tan K, Nair A, Zhou Y, Liu X, Thomas S, Qian P. Thermal effects of pulse field ablation: a comparative study of 4 catheters in thermochromic gel myocardial phantom model. Heart Rhythm. 2026.","DOI":"10.1016\/j.hrthm.2026.03.188"},{"issue":"7 Pt 2","key":"2434_CR14","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.jacep.2024.05.001","volume":"10","author":"P Osmancik","year":"2024","unstructured":"Osmancik P, Bacova B, Herman D, Hozman M, Fiserova I, Hassouna S, et al. Periprocedural Intravascular Hemolysis During Atrial Fibrillation Ablation: A Comparison of Pulsed Field With Radiofrequency Ablation. JACC Clin Electrophysiol. 2024;10(7 Pt 2):1660\u201371.","journal-title":"JACC Clin Electrophysiol"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-026-02434-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-026-02434-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-026-02434-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:30:47Z","timestamp":1791358247000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-026-02434-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2434"],"URL":"https:\/\/doi.org\/10.1007\/s10840-026-02434-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-10484882\/v1","asserted-by":"object"}]},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"26 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics Committees\u2019 approval and informed consent were obtained as per each institutional requirements prior to enrollment. Procedures were performed as per established institutional requirements and guidelines.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained as per institutional requirements prior to enrolment. Consent to publish was included in the patients\u2019 informed consent.","order":2,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by CRC EP. PQ was supported by an NSW Health EMCR Grant, Heart Foundation of Australia Postdoctoral Fellowship (105197), NHMRC Investigator Emerging Leadership 1 grant (GNT2018376) and McCusker Foundation grant. Drs. Ahmad, Aryana, Gould, Qian, and Thomas have received consulting fees from CRC EP, the manufacturer of the ablation technology investigated in this trial (Modest).","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}